Viridian Therapeutics
VRDN
28 hedge funds and large institutions have $11.9M invested in Viridian Therapeutics in 2020 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 6 closing their positions.
137% more capital invested
Capital invested by funds: $5.05M → $11.9M (+$6.9M)
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
4% more funds holding
Funds holding: 27 → 28 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.07% less ownership
Funds ownership: 1.42% → 1.35% (-0.07%)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$82.8K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$48.6K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$45.4K |
| 4 |
Squarepoint
New York
|
+$39.3K |
| 5 |
GPFA
Game Plan Financial Advisors
Westlake,
Ohio
|
+$18.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$563K |
| 2 |
Renaissance Technologies
New York
|
-$36.6K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$20K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$19.9K |
| 5 |
Mercer Global Advisors
Denver,
Colorado
|
-$6K |
VRDN Hedge Fund Activity: Q2 2020 in Review
28 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q2 2020, worth a combined $11.9M — up 137% from $5.05M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new VRDN positions and 6 closed out — a net gain of 1 holder — while 5 added to existing stakes and 7 trimmed.
The largest buyer was BlackRock, adding an estimated $82.8K. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $563K sold.
- 28 institutional investors held Viridian Therapeutics (VRDN) as of Q2 2020, up from 27 in Q1 2020.
- Funds reported $11.9M of Viridian Therapeutics stock for Q2 2020, up 137% quarter-over-quarter.
- 7 funds opened new Viridian Therapeutics positions in Q2 2020 and 6 closed out, a net change of +1 holder.
- The largest Viridian Therapeutics buyer in Q2 2020 was BlackRock, an estimated $82.8K added.
- The largest Viridian Therapeutics seller in Q2 2020 was Alyeska Investment Group, an estimated $563K sold.
Based on aggregated 13F filings for Q2 2020.